CPMP note for guidance: clinical trials on the medicinal products in the treatment of cardiac failure.
Shah
R
R
Medicines Control Agency, London, United Kingdom.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D005500:Follow-Up Studies; D017408:Guidelines as Topic; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D006113:United Kingdom; D017307:Xamoterol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D017307:Xamoterol; D003577:Cytochrome P-450 Enzyme System